Last reviewed · How we verify

Artesunate 4

University of Oxford · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Artesunate 4 is a Small molecule drug developed by University of Oxford. It is currently FDA-approved.

Artesunate is a small molecule medication with an unknown mechanism of action, used to treat conditions such as malaria, uncomplicated Plasmodium falciparum malaria, and anemia. It is available under various brand names, including Artecom, and has been studied in clinical trials for its efficacy and bioequivalence in different formulations.

At a glance

Generic nameArtesunate 4
SponsorUniversity of Oxford
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artesunate 4

What is Artesunate 4?

Artesunate 4 is a Small molecule drug developed by University of Oxford.

Who makes Artesunate 4?

Artesunate 4 is developed and marketed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

What development phase is Artesunate 4 in?

Artesunate 4 is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing